Advances in nonhormone therapies provide women with more options for managing hot flashes

September 28, 2020

CLEVELAND, Ohio (September 28, 2020)--Although many women manage menopause symptoms with hormone therapy, increasing numbers of women are considering nonhormone options. Dr. Susan Reed from the University of Washington School of Medicine is a featured speaker during the 2020 Pre-Meeting Symposium of The North American Menopause Society (NAMS) and will discuss the latest advances in nonhormone hot flash management. One of the more promising drug developments targets the KNDy neuron complex.

According to Dr. Reed, who serves as the vice chair of the Department of Obstetrics and Gynecology at the University of Washington School of Medicine in Seattle, successful nonhormone therapies that preceded work in the area of kisspeptin, neurokinin B, and dynorphin (KNDy) neuron targeting include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), gabapentin, oxybutynin, and clonidine. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors given in higher doses are primarily used for depression management. GABAergic drugs, such as gabapentin and pregabalin, are currently used for pain syndromes and seizures. Oxybutynin is FDA approved for overactive bladder. New research focused on a better understanding of the physiology of menopause hot flashes is leading to the development of new nonhormone pharmacotherapies.

In her presentation during the 2020 Pre-Meeting Symposium, Dr. Reed will summarize progress on drug development targeting the KNDy neuron complex, adverse effects of these novel drugs, and their long-term potential as nonhormone therapies for menopause symptoms.

"At menopause, diminished estrogen causes the KNDy neurons to go into hyperdrive, activating the adjacent thermoregulatory center, resulting in hot flashes," explains Dr. Reed. "To date, there are no FDA-approved products for menopause directed toward the KNDy neuron complex, but drugs first developed for pain control and for mood disorders acting via KNDy are under investigation for the treatment of vasomotor symptoms in the United States and Europe and hold great promise."

Beyond her discussion on the future of these new treatments, Dr. Reed will also present new data on the effectiveness of oxybutynin, as well as existing data on SSRIs/SNRIs, GABAergics, and clonidine.

"Hot flashes are one of the most common complaints of postmenopausal women, adversely affecting their overall quality of life," says Dr. Stephanie Faubion, NAMS medical director. "Although hormone therapy remains one of the most-proven methods of treatment, some women are unwilling or unable to take hormones. That's why this presentation on the latest innovations in the nonhormone treatment options for hot flashes is so valuable."

Drs. Reed and Faubion are available for interviews before the presentation during the virtual annual meeting which starts on September 28.
For more information on menopause and healthy aging, visit

Founded in 1989, The North American Menopause Society (NAMS) is North America's leading nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond through an understanding of menopause and healthy aging. Its multidisciplinary membership of 2,000 leaders in the field--including clinical and basic science experts from medicine, nursing, sociology, psychology, nutrition, anthropology, epidemiology, pharmacy, and education--makes NAMS uniquely qualified to serve as the definitive resource for health professionals and the public for accurate, unbiased information about menopause and healthy aging. To learn more about NAMS, visit

The North American Menopause Society (NAMS)

Related Menopause Articles from Brightsurf:

Cannabis use for menopause symptom management
CLEVELAND, Ohio (September 28, 2020)--As legislation relaxes regarding cannabis, it is being used to manage numerous chronic health conditions and mood symptoms.

Could your menopause symptoms be hard on your heart?
Menopause is accompanied by numerous symptoms that can interfere with a woman's quality of life, but can they also cause health problems?

Research provides new insights into menopause and weight gain
Can women in menopause get the benefits of hormone replacement therapy without the health risks?

Executive function in women post-menopause
Assessing adverse childhood experiences and current anxiety and depression symptoms may help ease cognitive distress in women who have undergone a surgical menopause for cancer risk-reduction, or RRSO, according to a new study published in Menopause.

An apple a day might help keep bothersome menopause symptoms away
A healthy diet rich in fruits and vegetables is known to benefit the human body in so many ways.

Menopause timing hard to determine in every third woman
Is it possible to investigate menopausal age, or not? In more than one in three women aged 50, the body provides no clear answer about the menopause, Swedish study shows.

Having less sex linked to earlier menopause
Women who engage in sexual activity weekly or monthly have a lower risk of entering menopause early relative to those who report having some form of sex less than monthly, according to a new UCL study.

Getting a good night's sleep complicated by menopause
The value of a good night's sleep can't be underestimated.

Early menopause predictor of heart disease
Women who reach menopause before the age of 50 have an increased risk of cardiovascular disease, according to researchers from The University of Queensland.

Microbes are a key marker of vaginal health during menopause
Certain species of bacteria are actually necessary to maintain vaginal health.

Read More: Menopause News and Menopause Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to